These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34098964)

  • 1. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
    Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
    J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
    Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
    Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
    Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
    Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
    Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
    Brunnström H; Johansson A; Westbom-Fremer S; Backman M; Djureinovic D; Patthey A; Isaksson-Mettävainio M; Gulyas M; Micke P
    Mod Pathol; 2017 Oct; 30(10):1411-1421. PubMed ID: 28664936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
    Taylor CR; Jadhav AP; Gholap A; Kamble G; Huang J; Gown A; Doshi I; Rimm DL
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):263-269. PubMed ID: 30640753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
    Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
    Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
    Liu J; Zheng Q; Mu X; Zuo Y; Xu B; Jin Y; Wang Y; Tian H; Yang Y; Xue Q; Huang Z; Chen L; Gu B; Hou X; Shen L; Guo Y; Li Y
    Sci Rep; 2021 Aug; 11(1):15907. PubMed ID: 34354151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
    Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
    Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
    Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N; Murakami S; Yokose T; Isaka T; Shinada K; Nagashima T; Adachi H; Shigefuku S; Murakami K; Miura J; Kikunishi N; Watabe K; Saito H; Ito H
    Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer.
    Haragan A; Parashar P; Bury D; Cross G; Gosney JR
    J Clin Pathol; 2024 Jan; 77(2):140-144. PubMed ID: 38071529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
    Shi L; Zhang SJ; Chen J; Lu SX; Fan XJ; Tong JH; Chow C; Tin EK; Chan SL; Chong CC; Lai PB; To KF; Wong N; Chan AW
    Mod Pathol; 2019 Nov; 32(11):1646-1656. PubMed ID: 31231126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.